Can-Fite's CF101 fails in PhIII dry eye study
This article was originally published in Scrip
Executive Summary
Israeli company Can-Fite BioPharma has announced that its lead candidate CF101 has failed to hit its efficacy endpoints in a Phase III study in dry eye syndrome.